

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-8. Canceled.

9. (Currently amended) A ~~use of an inhibitor of soluble epoxide hydrolase ("sEH") for the manufacture of a medicament to inhibit or slow progression~~ method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase ("sEH").

10. (Currently amended) A ~~use~~ method of claim 9, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

11. (Currently amended) A ~~use~~ method of claim 9, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

12. (Currently amended) A ~~use~~ method of claim 9, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

13. (Currently amended) A ~~use~~ method of claim 9, wherein the condition is asthma.

14. (Currently amended) A ~~use~~ method of claim 9, wherein said inhibitor of sEH is selected from the group consisting of an adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

15. (Currently amended) A ~~use~~ method of claim 9, wherein the ~~medicament is~~ inhibitor is in a slow release formulation.

16. (Currently amended) A ~~use~~ method of claim 9, ~~wherein said medicament further comprises~~ further comprising administering a cis-epoxyeicosantrienoic acid ("EET").

17. (Currently amended) A ~~use~~ method of claim 9, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

18. (Currently amended) A ~~use~~ method of claim 9, wherein said EET is 14R,15S-EE T.

19. (Currently amended) A ~~use of a nucleic acid that inhibits expression of soluble epoxide hydrolase ("sEH") for the manufacture of a medicament for inhibiting or slowing progression~~ method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of a nucleic acid that inhibits expression of soluble epoxide hydrolase ("sEH").

20. (Currently amended) A ~~use~~ method of claim 19, wherein the nucleic acid is a small interfering RNA.

21. (Currently amended) A ~~use~~ method of claim 19, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

22. (Currently amended) A ~~use~~ method of claim 19, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

23. (Currently amended) A ~~use~~ method of claim 19, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

24. (Currently amended) A ~~use~~ method of claim 19, wherein the condition is asthma.

25. (Withdrawn) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, said method comprising administering an inhibitor of soluble epoxide hydrolase ("sEH") and a *cis*-epoxyeicosantrienoic acid ("EET") to a person in need thereof.

26. (Withdrawn) A method of claim 25, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

27. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

28. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

29. (Withdrawn) A method of claim 25, wherein the condition is asthma.

30. (Withdrawn) A method of claim 25, wherein the inhibitor of sEH or the EET, or both, is in a material which releases the inhibitor over time.

31. (Withdrawn) A method of claim 25, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

32. (Withdrawn) A method of claim 25, wherein said EET is 14R,15S-EET.

33. (Withdrawn) A method of claim 25, wherein the inhibitor is administered orally.

34. (Withdrawn) A method of claim 25, wherein the inhibitor is administered in a total daily dose from about 0.001 mg/kg to about 100 mg/kg body weight.

35. (Withdrawn) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and

asthma, said method comprising administering to a person in need thereof a nucleic acid which inhibits expression of a gene encoding soluble epoxide hydrolase ("sEH"), and a *cis*-epoxyeicosantrienoic acid ("EET").

36. (Withdrawn) A method of claim 35, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

37. (Withdrawn) A method of claim 35, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

38. (Withdrawn) A method of claim 35, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

39. (Withdrawn) A method of claim 35, wherein the condition is asthma.

40. (Withdrawn) A method of claim 35, wherein the nucleic acid is a small interfering RNA ("siRNA").